source
- Minghui Pharma sells Japanese rights to its Phase 3 thyroid eye disease drug for $110 million upfrontMinghui Pharmaceutical, a Shanghai‑based biotech, has agreed to transfer the Japanese commercial rights for its late‑stage thyroid eye disease candidate to a specialty pharmaceutical company. The…
- Democrats Gain Senate Control, Poised to Reverse Trump Health Care PoliciesDemocrats secured a Senate majority with at least 51 seats after Tuesday's election, ending the Republican trifecta of power. The new majority equips Democrats with oversight tools and the ability…